10 research outputs found
Additional file 2: of In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself
Figure S2. Influence of PTEN-∆ and PTEN on proliferation. Proliferation was determined by BrdU incorporation. Differences are shown as percentage of the transfection control cells (pcDNA3 transfected cells). (PDF 90 kb
Additional file 1: of In renal cell carcinoma the PTEN splice variant PTEN-Î shows similar function as the tumor suppressor PTEN itself
Figure S1. Western blot of A498 and 786-O cells. Protein extracts of A498 and 786-O cells were analyzed concerning the expression value of PTEN. (PDF 89 kb
Additional file 3: of In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself
Figure S3. Human phospho-kinase array (Roche) of transfected 786-O and A498 cells. Protein extracts were obtained from PTEN-Δ and PTEN transfected cells and analyzed concerning the phosphorylation status of 46 intracellular signaling kinases. The activity of the kinases AKT, JNK and p38 are highlighted with red boxes. (PDF 111 kb
DataSheet_1_Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis.docx
IntroductionVulvar cancer carries a favourable prognosis in early stages. However, therapeutic options for advanced or recurrent cases are limited despite a variety of therapeutic modalities, such as extensive surgical resection, chemotherapy, and radiotherapy. The most important emerging treatment modalities are immune checkpoint inhibitors. This systematic review and meta-analysis aims to assess the efficacy and safety of pembrolizumab, an immune checkpoint inhibitor, in women with advanced vulvar cancer.Materials and methodsFollowing a comprehensive search, review, and appraisal, two relevant single-arm studies were included. Meta-analysis was conducted using R4.3.0 software and RStudio 2023.03.0, presenting the overall effect size with a 95% confidence interval. Heterogeneity was assessed using I2 and the Cochrane Q χ2 statistics.ResultsOut of 154 studies screened for eligibility, two single-arm studies involving 119 patients receiving pembrolizumab for advanced vulvar cancer were included. The pooled objective response rate (ORR) was overall 10% (95% CI: 0.00-0.84) and 9% (95% CI: 0.00-0.89) in the PD-L1 positive subgroup. In the intention-to-treat (ITT) population, 31% (95% CI: 0.04-0.85) exhibited any clinical benefit (complete response, partial response, or stable disease). In the ITT population at six months, progression-free survival (PFS) was 19% (95% CI: 0.01-0.82), and overall survival (OS) was 48% (95% CI: 0.08-0.90). At 12 months, PFS decreased to 9% (95% CI: 0.00-0.85), and OS was 33% (95% CI: 0.04-0.85). No statistically significant heterogeneity was observed in PFS and OS analyses.Discussion and conclusionThis study suggests that one-third of women with advanced or recurrent vulvar cancer may, without the influence of PD-L1 status, benefit from pembrolizumab treatment despite a decline in both PFS and OS at 12 months. These findings provide support for considering pembrolizumab in the treatment paradigm for this specific subset of cancer patients.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023391888</p
Additional file 7: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population
Table S5. Univariable Cox regression analysis for distant disease-free survival. (DOCX 16 kb
Additional file 3: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population
Table S2. The primer and probe sequences used for mRNA quantification. (DOCX 13 kb
Additional file 5: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population
Table S3. Associations between patient and tumor characteristics and cancer median FOXP3 expression. (DOCX 17 kb
Additional file 1: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population
Table S1. Associations between median cancer CXCL13 expression and patient and tumor characteristics in triple-negative patients enrolled in HE10/97. (DOCX 15 kb
Additional file 6: of Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population
Table S4. Associations between patient and tumor characteristics and cancer median CD4 expression. (DOCX 16 kb
Table_1_Effects of intermittent fasting on quality of life tolerance of chemotherapy in patients with gynecological cancers: study protocol of a randomized-controlled multi-center trial.docx
Fatigue is a very common side effect during intravenous chemotherapy. Unfortunately, only few effective therapeutic options are available, mostly based on daily activity. In our pilot trial we were able to demonstrate that intermittent fasting can reduce fatigue in healthy people, thus we aimed to assess the effects of the fasting dietary on quality of life during chemotherapy in patients with gynecological cancer, especially on the domain of fatigue. The IFAST trial is designed as a prospective, randomized-controlled, multi-center trial. Participation will be offered to women with gynecological cancers (breast cancer, ovarian cancer including peritoneal and fallopian tube cancers, endometrial cancer and cervical cancer) who are planned to receive intravenous chemotherapy for at least three months. Eligible patients will be randomized 1:1, stratified by tumor type and study center. Primary endpoint is the difference in mean change in fatigue, assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT- FS©). Exploratory secondary endpoints will include general Quality of Life impairment, tolerance of chemotherapy, immunological changes, peripheral cell damage in blood cells, as well as tumor response to chemotherapy. There is new evidence that prolonged fasting periods of 46-96 hours during chemotherapy can positively influence the quality of life during chemotherapy. However, these fasting regiments are not feasible for many patients. Intermittent fasting could be a feasible (manageable) option for many patients to actively improve their quality of life and tolerance to chemotherapy and possibly even enhance the effectiveness of chemotherapy.Trial Registrationhttps://drks.de, identifier DRKS00031429.</p